Zuzanna Juris v. Inamed Corporation

CourtCourt of Appeals for the Eleventh Circuit
DecidedJuly 6, 2012
Docket10-12665
StatusPublished

This text of Zuzanna Juris v. Inamed Corporation (Zuzanna Juris v. Inamed Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zuzanna Juris v. Inamed Corporation, (11th Cir. 2012).

Opinion

Case: 10-12665 Date Filed: 07/06/2012 Page: 1 of 89

[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT FILED ________________________ U.S. COURT OF APPEALS ELEVENTH CIRCUIT JULY 6, 2012 No. 10-12665 JOHN LEY ________________________ CLERK

D. C. Docket No. 2:97-cv-11441-RDP

ZUZANNA JURIS,

Plaintiff-Appellant,

versus

INAMED CORPORATION, MCGHAN MEDICAL CORP., et al.,

Defendants-Appellees.

________________________

Appeal from the United States District Court for the Northern District of Alabama _________________________

(July 6, 2012)

Before TJOFLAT, CARNES and ANDERSON, Circuit Judges.

ANDERSON, Circuit Judge:

In 1999, the United States District Court for the Northern District of

Alabama approved a mandatory, limited fund class settlement, which resolved tens Case: 10-12665 Date Filed: 07/06/2012 Page: 2 of 89

of thousands of claims arising out of injuries allegedly caused by defective

silicone breast implants manufactured by Inamed Corporation (“Inamed”).

Several years later, in 2006, Zuzanna Juris filed an individual action in California

state court against Inamed and Allergan, Inc. (“Allergan”), Inamed’s successor,

alleging injuries caused by her Inamed implants. The defendants contended that

Juris’s lawsuit was barred because the 1999 class settlement resolved her claims;

Juris posited that she could avoid the settlement’s res judicata effect on due

process grounds. The district court held that the class settlement precluded Juris

from prosecuting the California case. This is Juris’s appeal.

For the reasons explained below, we affirm.

I. BACKGROUND 1

Well after the creation of silicone breast implants, women implanted with

them began claiming that leaking gel was causing them various diseases. In 1992,

the Food and Drug Administration (“FDA”) first banned the use of silicone gel

implants, and a flood of litigation followed. The FDA relaxed the ban later that

year to permit the use of such implants for specified medical procedures. The

1 The district court should be commended for the comprehensive narrative in which it set forth this case’s complex procedural and factual history. Throughout Part I.A through E, we borrow in large part from the findings of fact in the district court’s memorandum opinion.

2 Case: 10-12665 Date Filed: 07/06/2012 Page: 3 of 89

number of lawsuits only increased further. As a result, the Judicial Panel on

Multidistrict Litigation consolidated more than 21,000 cases against various breast

implant manufacturers for pretrial proceedings and transferred them to District

Judge Sam Pointer in the Northern District of Alabama.2 See In re Silicone Gel

Breast Implants Prods. Liab. Litig., 793 F. Supp. 1098 (J.P.M.L. 1992); In re

Silicone Breast Implants Prods. Liab. Litig., MDL 926, 2:92-cv-10000 (N.D.

Ala.). The transfer included all pending federal lawsuits against Inamed regarding

allegedly defective implants.

A. Inamed’s Pre-Settlement Financial Condition

In 1991, women with Inamed breast implants began filing individual suits

against Inamed and its subsidiaries. The litigation ballooned. At one point, more

than 15,000 lawsuits were pending against Inamed across the country. Breast

implant litigation forced the company to divert substantial capital to funding

defense efforts. In 1994, in an attempt to stem the tide, Inamed and the plaintiffs’

settlement committee negotiated a global settlement agreement, which would have

required Inamed to pay $1 million per year for twenty-five years. Anticipating

2 Troubled by allegations of forum shopping, litigation strategies, and underlying motives, the multidistrict panel rejected the forum preferences of both sides and independently assigned the case to Judge Pointer in light of his experience and reputation.

3 Case: 10-12665 Date Filed: 07/06/2012 Page: 4 of 89

approval of that proposal, Inamed booked the $25 million annuity as a contingent

liability in the amount of $9.2 million (the present value of twenty-five annual

payments of $1 million). Inamed sought to certify a limited fund settlement class

pursuant to Federal Rule of Civil Procedure 23(b)(1)(B) in an effort to secure a

mandatory, global resolution of all present and future claims. The plaintiffs’

settlement committee retained Ernst & Young to review Inamed’s finances and

determine whether limited fund treatment was appropriate. Ernst & Young issued

a report confirming Inamed’s claims that its liabilities, both operational and

litigation-related, dwarfed its assets. Counsel for the plaintiffs did not dispute this.

However, they questioned whether the $9.2 million present value contribution was

prudent considering Inamed’s potential future earnings. Disagreement yielded

further negotiations, and the possibility of a global settlement languished.

Responding to its growing financial troubles, in 1996, Inamed approached a

high risk investment group and raised $35 million through the private placement

of senior secured convertible notes. The notes were senior to all claims, including

operational liabilities and tort claims, and were secured by interests in

substantially all of Inamed’s assets. Pursuant to the terms of the offering, Inamed

deposited $15 million in escrow for the sole purpose of financing a non-opt-out

class settlement if approved before January 23, 1997. That temporal condition

4 Case: 10-12665 Date Filed: 07/06/2012 Page: 5 of 89

was not met. Inamed returned the $15 million to the noteholders in exchange for

warrants to purchase Inamed common stock in the event a mandatory class

settlement was later approved. Inamed quickly exhausted the balance, $20

million, which provided necessary cash to stay in business and cover expenditures

related to inventory, payments to vendors, and other operational items.

In January of 1997, Inamed secured an additional $6.2 million through

another private debt placement. All proceeds were immediately applied towards

day-to-day operational expenses and payments against past-due income tax

liabilities. Around this time, Inamed defaulted on its repayment obligations under

the senior secured notes and its stock price dropped. The company continued to

explore options for raising working capital. However, between the senior secured

noteholders exercising their veto authority over Inamed’s ability to raise capital

through equity offerings and, more generally, the unavailability of commercially

reasonable lending opportunities given the company’s dire financial predicament,

Inamed’s only option was to borrow approximately $10 million from an entity

associated with its former chairman.

Throughout the 1990s, each audit letter prepared by Inamed’s independent

auditing firm, Coopers & Lybrand, included a qualified opinion expressing

“substantial doubt about the Company’s ability to continue as a going concern.”

5 Case: 10-12665 Date Filed: 07/06/2012 Page: 6 of 89

For fiscal years 1995, 1996, and 1997, Inamed reported pre-tax operating losses of

$8.6 million, $6.0 million, and $6.6 million, respectively. By the end of 1997, the

company’s consolidated book value—subtracting liabilities from assets—was

negative $10.9 million.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Twigg v. Sears, Roebuck & Co.
153 F.3d 1222 (Eleventh Circuit, 1998)
Norfolk Southern Corporation v. Chevron Chemical
371 F.3d 1285 (Eleventh Circuit, 2004)
Tom L. Ashlock v. Conseco Services, LLC
381 F.3d 1251 (Eleventh Circuit, 2004)
Joana C. Sepulveda v. U.S. Atty. Gen.
401 F.3d 1226 (Eleventh Circuit, 2005)
Bayshore Ford Trucks Sales, Inc. v. Ford Motor Co.
471 F.3d 1233 (Eleventh Circuit, 2006)
Adams v. Southern Farm Bureau Life Insurance
493 F.3d 1276 (Eleventh Circuit, 2007)
Douglas F. Martin v. Leonidas Pahiakos
490 F.3d 1272 (Eleventh Circuit, 2007)
Smith v. Swormstedt
57 U.S. 288 (Supreme Court, 1854)
Hartford Life Insurance v. IBS
237 U.S. 662 (Supreme Court, 1915)
Hansberry v. Lee
311 U.S. 32 (Supreme Court, 1940)
Mullane v. Central Hanover Bank & Trust Co.
339 U.S. 306 (Supreme Court, 1950)
Dombrowski v. Pfister
380 U.S. 479 (Supreme Court, 1965)
Federated Department Stores, Inc. v. Moitie
452 U.S. 394 (Supreme Court, 1981)
Phillips Petroleum Co. v. Shutts
472 U.S. 797 (Supreme Court, 1985)
Ticor Title Insurance v. Brown
511 U.S. 117 (Supreme Court, 1994)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
Ortiz v. Fibreboard Corp.
527 U.S. 815 (Supreme Court, 1999)
Dow Chemical Co. v. Stephenson
539 U.S. 111 (Supreme Court, 2003)
Pelt v. Utah
539 F.3d 1271 (Tenth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Zuzanna Juris v. Inamed Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zuzanna-juris-v-inamed-corporation-ca11-2012.